COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
30/10/2025
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the [...]
Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
30/10/2025
HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its [...]
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for [...]
Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
30/10/2025
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior [...]
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
30/10/2025
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, [...]
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
30/10/2025
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that [...]
Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
30/10/2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on [...]
Cambridge Atomworks is delighted to announce the appointment of Mr Alistair Pettey as a non-executive director
30/10/2025
CAMBRIDGE, United Kingdom, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Alistair will lead on the growth and capital strategy for Cambridge Atomworks. Alistair has a passion for investing in companies that have a strong focus in [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2025
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
30/10/2025
$12.9 million in third quarter PYRUKYND ® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision [...]
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
30/10/2025
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific LOUISVILLE, Colo., Oct. 30, 2025 ( [...]
TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board
30/10/2025
Basel, October 30, 2025 – TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Kenneth C. Anderson, MD, a globally recognized leader in multiple myeloma research, to the company’s Scientific Advisory [...]
Integra LifeSciences Reports Third Quarter 2025 Financial Results
30/10/2025
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending [...]
Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
30/10/2025
AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer [...]
Amneal Reports Third Quarter 2025 Financial Results
30/10/2025
‒ Q3 2025 Net Revenue of $785 million ; GAAP Net Income of $2 million ; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million ; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ [...]
Novo Nordisk submits proposal to acquire Metsera, Inc.
30/10/2025
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera). The acquisition of Metsera, including its early and development-stage incretin and [...]

Pages